The Australasian Sleep Association has updated its consensus statement on the safe use of respiratory therapy and NIV to minimise aerosolisation of COVID-19.
The statement acknowledges both the relatively low rates of community transmission of COVID-19 in Australia and New Zealand and the unique challenges of managing hotel quarantine for people returning from overseas and at much higher risk of COVID-19.
Some of the recommendations include:
Nebulisers
- Nebulisation of bronchodilators and steroids is not necessary for most patients and should be replaced by metered dose inhaler (MDI) with a spacer.
- People with suspected or known COVID-19 requiring use of nebulisation for acute medical symptoms should be managed in the highest level isolation available. Given this level of care is not available at home or in hotel quarantine, transfer to an acute hospital for expert care is required.
High flow oxygen (hospital based)
- The lowest flow rate of oxygen should be used to maintain oxygen saturations to minimise risk of viral aerosolisation and/or dispersal.
- If HFNO is to be used in a patient with suspected or known COVID-19, the patient should be fitted with an interface to minimise leak in the highest level of isolation available (class N-negative pressure room is optimal), with airborne and droplet PPE precautions for health care personnel.
NIV for acute or chronic respiratory failure